

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) An isolated RNase A superfamily polypeptide having an N-terminus of the sequence: X¹X²SLX³V (SEQ ID NO:9), wherein X¹ represents methionine, X² represents glycine ~~or is absent~~, and X³ represents any amino acid residue, said RNase A superfamily polypeptide being selectively toxic to a proliferating endothelial cell and having at least 90% sequence identity to SEQ ID NO:4.

2-3. (canceled)

4. (previously presented) An isolated RNase A superfamily polypeptide of claim 1 having SEQ ID NO:4.

5-6. (canceled)

7. (previously presented) An isolated RNase A superfamily polypeptide of claim 1 wherein the N-terminus is MGSLHV (SEQ ID NO:10).

8. (previously presented) An isolated RNase A superfamily polypeptide of claim 1 wherein the N-terminus is attached to the eosinophil derived neurotoxin (EDN) protein.

9. (previously presented) An isolated RNase A superfamily polypeptide of claim 1 wherein the proliferating endothelial cell is a neoplastic endothelial cell.

10. (previously presented) An isolated RNase A superfamily polypeptide of claim 1 wherein the proliferating endothelial cell is a non-neoplastic endothelial cell.

11. (previously presented) An isolated RNase A superfamily polypeptide of claim 9 wherein the neoplastic endothelial cell is a Kaposi sarcoma KS Y-1 cell.

12. (previously presented) An isolated RNase A superfamily polypeptide of claim 9 wherein the neoplastic endothelial cell is a KS Y-3 cell.

13. (previously presented) An isolated RNase A superfamily polypeptide of claim 9 wherein the neoplastic endothelial cell is selected from the group consisting of KS 1, KS 2, KS 3, KS 4, KS 5, and KS 6 cells.

14. (currently amended) A pharmaceutical composition comprising
a. a unit dosage RNase A superfamily polypeptide comprising an N-terminus of the sequence: $X^1X^2SLX^3V$ (SEQ ID NO:9), wherein X^1 represents methionine, X^2 represents glycine or is absent, and X^3 represents any amino acid residue, said RNase A superfamily polypeptide being selectively toxic to a proliferating endothelial cell and having at least 90% sequence identity to SEQ ID NO:4; and
b. a pharmaceutically acceptable carrier.

15-21. (canceled)